- Home
- DTIL vs IFRX Comparison
DTIL vs IFRX Comparison
Compare DTIL & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- IFRX
- Stock Information
- Founded
- DTIL 2006
- IFRX 2007
- Country
- DTIL United States
- IFRX Germany
- Employees
- DTIL N/A
- IFRX N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- IFRX Health Care
- Exchange
- DTIL Nasdaq
- IFRX Nasdaq
- Market Cap
- DTIL 55.3M
- IFRX 53.5M
- IPO Year
- DTIL 2019
- IFRX 2017
- Fundamental
- Price
- DTIL $5.39
- IFRX $1.25
- Analyst Decision
- DTIL Strong Buy
- IFRX Strong Buy
- Analyst Count
- DTIL 2
- IFRX 5
- Target Price
- DTIL $47.00
- IFRX $7.40
- AVG Volume (30 Days)
- DTIL 84.4K
- IFRX 469.4K
- Earning Date
- DTIL 11-03-2025
- IFRX 11-07-2025
- Dividend Yield
- DTIL N/A
- IFRX N/A
- EPS Growth
- DTIL N/A
- IFRX N/A
- EPS
- DTIL N/A
- IFRX N/A
- Revenue
- DTIL $1,261,000.00
- IFRX $191,224.00
- Revenue This Year
- DTIL N/A
- IFRX N/A
- Revenue Next Year
- DTIL $135.19
- IFRX $1,216.24
- P/E Ratio
- DTIL N/A
- IFRX N/A
- Revenue Growth
- DTIL N/A
- IFRX 54.36
- 52 Week Low
- DTIL $3.61
- IFRX $0.71
- 52 Week High
- DTIL $9.20
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- DTIL 56.34
- IFRX 45.60
- Support Level
- DTIL $5.26
- IFRX $1.34
- Resistance Level
- DTIL $5.94
- IFRX $1.44
- Average True Range (ATR)
- DTIL 0.22
- IFRX 0.14
- MACD
- DTIL 0.02
- IFRX -0.03
- Stochastic Oscillator
- DTIL 55.35
- IFRX 21.00
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.